{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-086034","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.682371+00:00","generated_at":"2026-06-12T18:26:02.712577+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rhythm Q2 2023 revenue $19.2M; BBS prescriptions top 425; eligible for $25M milestone payment","bullets":["Q2 2023 net product revenue $19.2M (vs $2.3M Q2 2022); net loss $46.7M ($0.82/share).","Achieved commercial sales milestone under RIFA with HealthCare Royalty, eligible for final $25M tranche.","Over 125 new BBS prescriptions in Q2 2023; >425 since FDA approval in June 2022.","Phase 3 hypothalamic obesity trial enrollment expected by Q4 2023; IND for RM-718 by end of 2023.","Cash, cash equivalents and short-term investments $253.6M as of June 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-086034","json":"https://secwatch.observer/filing/0001104659-23-086034.json","markdown":"https://secwatch.observer/filing/0001104659-23-086034.md","text":"https://secwatch.observer/filing/0001104659-23-086034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923086034/0001104659-23-086034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923086034/tm2322430d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T18:26:02.712577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87ff36508e35effe40dbbd88dfae241367e9e7b8","claim":"RHYTHM PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $19.2 million.","evidence_excerpt":"Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update -- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923086034/0001104659-23-086034-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$19.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}